News
MLLCF
3.500
NaN%
--
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
TipRanks · 03/16 10:26
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
TipRanks · 03/16 05:45
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
TipRanks · 03/13 16:15
Molecular Partners (MOLN) Gets a Buy from Clear Street
TipRanks · 03/13 11:19
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
TipRanks · 02/26 21:45
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
TipRanks · 02/26 10:45
Molecular Partners presents first imaging, dosimetry data of MP0712
TipRanks · 02/02 10:30
Molecular Partners initiated with a Buy at H.C. Wainwright
TipRanks · 01/27 11:11
Molecular Partners (MOLN) Gets a Buy from LifeSci Capital
TipRanks · 01/20 13:38
Molecular Partners provided update on latest progress, 2026 milestones
TipRanks · 01/11 20:55
Molecular Partners Advances DLL3 Radioligand Program With New Phase 1/2a Cancer Trial
TipRanks · 01/09 16:32
Molecular Partners forms Scientific Advisory Board
TipRanks · 12/11/2025 12:20
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
TipRanks · 12/08/2025 18:05
Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
TipRanks · 12/08/2025 17:20
Molecular Partners (MOLN) Receives a Buy from Clear Street
TipRanks · 12/08/2025 13:15
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
TipRanks · 12/08/2025 12:41
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
TipRanks · 12/07/2025 18:35
Buy Rating for Molecular Partners: Innovative Pipeline and Promising SCLC Advancements
TipRanks · 11/12/2025 19:15
Molecular Partners presents new MP0712 data
TipRanks · 11/12/2025 10:50
Molecular Partners: Promising Pipeline and Strategic Partnerships Justify Buy Rating
TipRanks · 10/28/2025 10:36
More
Webull provides a variety of real-time MLLCF stock news. You can receive the latest news about Molecular Partnr through multiple platforms. This information may help you make smarter investment decisions.
About MLLCF
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.